Article

mTOR inhibition enhances the antitumor efficacy of RAF dimer-MEK blockade by inhibiting the ATF4-MTHFD2 pathway

2025-07-18

Abstract excerpt

<title>Abstract</title> <p>RAF monomer inhibitors are clinically approved for the treatment of BRAF<sup>V600</sup>-mutant melanoma in combination with a MEK inhibitor, but ineffective in other melanoma subtypes. Moreover, RAF dimer inhibitors, such as belvarafenib, when combined with MEK inhibitors (cobimetinib) have promising but limited efficacy in non-<italic>BRAF</italic>-mutant melanomas. Here, we report tha...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5e362e98-6f3e-5f1c-a878-23a6421ee40e
DOI: 10.21203/rs.3.rs-6857127/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

mTOR inhibition enhances the antitumor efficacy of RAF dimer-MEK blockade by inhibiting the ATF4-MTHFD2 pathwayDOI 10.21203/rs.3.rs-6857127/v1Read

Melanoma with genetic alterations beyond the BRAFV600 mutation: management and new insights.Semantic proximity Read

Combination of the Novel RAF Dimer Inhibitor Brimarafenib With the MEK Inhibitor Mirdametinib Is Effective Against NRAS Mutant Melanoma.Semantic proximity Read

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.Semantic proximity Read

Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.Semantic proximity Read

BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.Semantic proximity Read

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors.Semantic proximity Read

Targeting the Raf kinases in human cancer: the Raf dimer dilemma.Semantic proximity Read

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.Semantic proximity Read

Computational-experimental repurposing reveals synergistic sorafenib/hydroxychloroquine response in KRAS-mutant breast cancer.Semantic proximity Read

Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers.Semantic proximity Read

Human melanoma cell lines that possess wild-type <i>BRAF</i> alleles but are dependent on <i>ERBB4</i> and <i>ERBB2</i>Semantic proximity Read

A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.Semantic proximity Read